Skip to main content
DONGWHA PHARM.CO.,LTD logo

DONGWHA PHARM.CO.,LTD — Investor Relations & Filings

Ticker · 000020 ISIN · KR7000020008 KO Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-05-03 Governance Information
Country KR South Korea
Listing KO 000020

About DONGWHA PHARM.CO.,LTD

https://www.dong-wha.co.kr

Dongwha Pharm is a pharmaceutical company engaged in the research, development, manufacturing, and sale of a diverse range of healthcare products. Its portfolio includes ethical (prescription) pharmaceuticals, over-the-counter (OTC) drugs, medical devices, quasi-drugs, health functional foods, cosmetics, and beverages. The company's research and development efforts focus on various therapeutic areas, including alimentary and cardiovascular systems. Dongwha Pharm actively pursues innovation through its drug pipeline, clinical trials, and strategic investments in emerging fields like digital therapeutics.

Recent filings

Filing Released Lang Actions
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 1% confidence The document is a regulatory disclosure from Dongwha Pharm regarding its 'Compliance Program (CP)' operational status, specifically detailing Q1 performance and Q2 plans. It is a standard corporate governance and regulatory compliance update filed with the exchange. Since it does not fit into specific categories like financial reports, M&A, or shareholder meetings, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2024-05-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM) for Dongwha Pharm. It details the approval of financial statements, dividend declarations, and the election of board members. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2024-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Dongwha Pharm. It provides the auditor's opinion (unqualified/appropriate), financial highlights (assets, liabilities, equity, profit/loss), and details regarding the accounting firm. While it contains financial data, it is specifically the regulatory filing of the audit report itself, which falls under the 'Audit Report / Information' category. FY 2023
2024-03-19 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Dongwha Pharm Co., Ltd. for the fiscal year ending December 31, 2023. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. While it contains financial statements, it is explicitly titled as an Audit Report and includes the auditor's opinion, which aligns with the 'Audit Report / Information' category. FY 2023
2024-03-19 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Dong-A Pharmaceutical. It contains the meeting agenda, details on director appointments, financial statements, and governance information. In the context of Korean regulatory filings (DART), this document is classified as a Proxy Solicitation & Information Statement (PSI) because it provides shareholders with the necessary information to vote on agenda items at the upcoming general meeting.
2024-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often referred to as a Proxy Solicitation Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the agenda, voting procedures, and proxy solicitation details. While it includes financial statements as reference material for the meeting, the primary purpose of the document is to solicit proxies for the AGM. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2024-03-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.